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Background: Psychiatric patients have more physical health problems and much shorter life expectancies
compared to the general population, due primarily to premature cardiovascular disease. A multi-causal model
which includes a higher prevalence of risk factors has provided a valid explanation. It takes into consideration not
only risks such as gender, age, and family history that are inherently non-modifiable, but also those such as obesity,
smoking, diabetes, hypertension, and dyslipidemia that are modifiable through behavioural changes and improved
care. Thus, it is crucial to focus on factors that increase cardiovascular risk. Obesity in particular has been associated
with both the lifestyle habits and the side effects of antipsychotic medications. The present systematic review and
meta-analysis aims at collecting and updating available evidence on the efficacy of non-pharmacological health
promotion programmes for psychotic patients in randomised clinical trials.
Methods: We systematically reviewed the randomised controlled trials from 1990 onward, in which
psychoeducational and/or cognitive-behavioural interventions aimed at weight loss or prevention of weight gain in
patients with psychosis had been compared to treatment as usual. We carried out a meta-analysis and pooled the
results of the studies with Body Mass Index as primary outcome.
Results: The results of the meta-analysis show an effect toward the experimental group. At the end of the
intervention phase there is a −0.98 kg/m2 reduction in the mean Body Mass Index of psychotic subjects. Notably,
prevention studies with individual psychoeducational programmes that include diet and/or physical activity seem
to have the highest impact.
Conclusions: When compared with treatment as usual in psychotic patients, preventive and individual lifestyle
interventions that include diet and physical activity generally prove to be effective in reducing weight. Physical
screening and monitoring programmes are well accepted by patients and can be implemented in a variety of
settings. A weight loss of 0.98 points in the Body Mass Index corresponds to a loss of 3.12% of the initial weight.
This percentage is below the 5% to 10% weight loss deemed sufficient to improve weight-related complications
such as hypertension, type II diabetes, and dyslipidemia. However, it is reported that outcomes associated with
metabolic risk factors may have greater health implications than weight changes alone. Therefore, in addition to
weight reduction, the assessment of metabolic parameters to monitor other independent risk factors should also
be integrated into physical health promotion and management in people with mental disorders.
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In comparison to the general population, psychiatric
patients, especially those with severe mental illness
(SMI) such as schizophrenia or bipolar disorder, have
worse physical health and a much shorter life expect-
ancy, due primarily to premature cardiovascular disease
(CVD) [1]. This finding has been explained with a multi-
causal model including a higher prevalence of risk fac-
tors, namely, high blood pressure, high plasma choles-
terol, obesity, smoking, diabetes, self-neglect tendencies,
unhealthy lifestyles, medication side-effects, and low
socio-economic status [2]. Risk factors for cardiovascular
morbidity and mortality include those that are inherently
non-modifiable (gender, age, family history) and those
that are modifiable through behavioural changes and
improved care (obesity, smoking, diabetes, hypertension,
and dyslipidemia) [3]. Sedentary lifestyles and limited ac-
cess to low-calorie, high-nutrient foods are but two
examples of potential modifiable contributors to obesity
in these patients [4].
In order to improve the long-term health of patients
with schizophrenia, given their increased risk of CVD, it
is imperative to focus attention on factors, such as obes-
ity, which further increase this risk [5]. Among indivi-
duals with schizophrenia and affective disorders, obesity
is 1.5-2 times higher than in the general population [6].
It has been associated not only with lifestyle habits but
also with the side effects of antipsychotic medications,
posing serious problems for physical and mental health,
including a higher mortality [7]. It has been demon-
strated that atypical antipsychotics (in particular, olanza-
pine and clozapine) contribute to weight gain, albeit
with different weight gain liabilities (ziprasidone, for ex-
ample, has the least) [8,9].
Two systematic reviews and meta-analyses exist on
this topic, one [10] on non-pharmacological interven-
tions for antipsychotic-induced weight gain and the
other [11] on both pharmacological and non-
pharmacological interventions. The first review [10]
addresses non-pharmacological interventions for
antipsychotic-induced weight gain in patients with
schizophrenia-spectrum disorders and it identifies 10
studies [12-21]. According to the authors, adjunctive
non-pharmacological interventions are effective in redu-
cing or attenuating antipsychotic-induced weight gain
when compared with treatment as usual in patients
with schizophrenia-spectrum disorders, and treatment
effects may be maintained through follow-ups [10]. The
second review [11] focuses on both pharmacological
and non-pharmacological interventions for weight re-
duction in schizophrenic patients or patients with SMI.
Evidence from 5 studies on non-pharmacological treat-
ments [12-14,16,19] has been gathered and updated to
2010. In this population, according to the authors, non-pharmacological interventions are possible and show ac-
ceptable compliance, although conclusions regarding the
intensity of the intervention cannot be made at this
stage, and thus there is the need for further randomised
controlled trials (RCTs) with long-term follow-ups [11].
However, the role of physical inactivity and poor diet as
independent risk factors for CVD infers the need for
non-pharmacological, lifestyle interventions regardless of
weight loss per se. According to the authors, there is
also insufficient evidence to support the general use of
pharmacological interventions for weight management
in people with schizophrenia [11].
Our systematic review and meta-analysis aims at col-
lecting and updating available evidence on the efficacy of
non-pharmacological health promotion programmes for
psychotic patients in randomised clinical trials, extend-
ing the search period beyond the years covered by the
other reviews. The twofold objective is to provide evi-
dence about the physical health of psychiatric patients
regarding excessive weight gain, in order to increase
awareness of this issue in both the scientific community
and the relevant stakeholders, and to expand the setting
up of effective intervention programmes. The main out-
come variable taken into consideration is Body Mass
Index (BMI), as specified and explained in Methods.
Methods
We reviewed RCTs from 1990 onward, which pertain to
psychoeducational and/or cognitive-behavioural inter-
ventions aimed at weight loss or prevention of weight
gain in patients with psychosis. The present work is part
of a larger systematic review (to be published) which,
after a wide-scale search of the literature on physical
health promotion interventions in psychiatric patients,
considers not only weight management interventions
but also interventions targeted at smoking, diet, physical
activity, and HIV prevention.
Eligibility criteria
We considered as eligible those randomised clinical
trials on the efficacy of weight management interven-
tions which had been published in English from 1990 up
to the date of the search. They included at least 50% of
adult subjects between the ages of 18 and 65 who,
according to the International Classification of Disorders
(ICD) [22] (codes F20-25, F28-31, F32.3, F33.3), had
been diagnosed with: schizophrenia and related disor-
ders (schyzotypal disorder, delusional disorder, acute and
transient psychotic disorders, induced psychotic dis-
order, schizoaffective disorder, other nonorganic psych-
otic disorders, unspecified nonorganic psychosis),
bipolar affective disorder, manic episode, depressive epi-
sode with psychotic symptoms or depressive disorder
with psychotic symptoms. We included in our review
Bonfioli et al. BMC Psychiatry 2012, 12:78 Page 3 of 12
http://www.biomedcentral.com/1471-244X/12/78those studies based on programmes aimed at weight re-
duction or prevention of weight gain through cognitive-
behavioural, psychoeducational, nutritional or physical
activity-based interventions. We excluded pharmaco-
logical interventions used to reduce weight.
The primary outcome considered is mean BMI (kg/
m2) of the groups at endpoint or change in BMI. Al-
though the use of BMI has limitations, because it does
not distinguish between fat and lean mass nor does it
adjust for age or sex, it is generally accepted as a reason-
able guide for clinical and epidemiologic purposes [23].
Search strategy
Only relevant studies from 1990 onward were consid-
ered, since previously published reviews had already cov-
ered the years prior to that date [10,11]. The following
search terms were used: psychosis and intervention and
health promotion or health education or physical health
or smoking or weight gain or exercise or HIV risk or
AIDS or infection. The searches were made on: a)
Pubmed, Web of Science, PsycInfo, Embase databases,
b) the Cochrane Library, c) reference section of retrieved
papers and review articles. The last search, performed in
May 2010, was later updated to cover the period up to
and including December 2011. To satisfy the specific
aims of this review, only studies relevant to weight gain
were selected from the results.
Study selection
Records retrieved from the search were screened by title.
Possible inclusions were screened by abstract. Full text
and relevant papers were then selected. Conference
abstracts and letters to the editor were excluded. For the
meta-analysis, we considered eligible RCTs on weight
management interventions. It was decided to contact the
authors of the studies that did not include sufficient data
for statistical analysis. Two reviewers discussed dubious
cases in order to reach an agreement on the inclusion of
studies.
Data extraction
Relevant data for the systematic review and for the
meta-analysis were extracted by 2 of our authors using
the format: 1) inclusion criteria; 2) characteristics of the
sample (diagnosis of the subjects, duration of the illness,
i.e., first episode or chronic psychosis); 3) number of
subjects that entered the analysis in the experimental
and in the control group; 4) number of drop-outs; 5)
type of intervention (prevention of weight gain or weight
loss, group or individual, cognitive-behavioural or psy-
choeducational, diet and/or physical activity); 6) mean
and standard deviation (SD) of the outcome considered
(BMI or BMI change) in both the experimental and the
control group at baseline and endpoint. We assessed therisk of bias based on the recommendations of the
Cochrane Handbook for Systematic Reviews of Interven-
tions [24].
The summary measure considered is the mean differ-
ence (MD) of the primary outcome (BMI or BMI
change) in the experimental and the control group at
baseline and endpoint. The statistical method used for
the meta-analysis is inverse variance, with a random-
effects approach, utilising RevMan (Cochrane Collabora-
tion’s software for meta-analyses). Heterogeneity is
investigated by the I2 statistic [25].
We hypothesized that the methodological quality of
the studies and some characteristics of the samples and
procedures used might influence the variability of
results. As a means of investigating the heterogeneity of
results and answering specific questions about particular
patient groups and types of interventions, we decided to
carry out subgroup analyses, making the following
comparisons:
– first episode psychosis vs. chronic psychosis;
– weight gain prevention vs. weight loss;
– group intervention vs. individual intervention;
– use of cognitive-behavioural therapy (CBT) vs.
psychoeducation;
– physical activity vs. no physical activity;
– diet vs. no diet.
We also decided to analyse the differences between ex-
perimental and control groups regarding the number of
drop-outs. We determined to assess the robustness of
the findings through sensitivity analyses.
Results
Seventeen RCTs were retrieved from the search. Five did
not provide sufficient information for meta-analysis
[18,26-29]. However, only 4 studies were excluded
[18,27-29] because in one case [26] the authors supplied
the missing data. For one study we had to impute SDs
from the pool of data [30]. Therefore, 13 RCTs were eli-
gible for inclusion [12-17,19-21,26,30-32]. More details
on the screening process can be found in Figure 1.
Five studies included CBT interventions whereas 8
included psychoeducational or other types of interven-
tion. Four studies evaluated an individual intervention
and 9 evaluated a group intervention. Four studies
included some physical activity and 3 included a diet. In
all the studies except one [31], the control group was
given treatment as usual and in some cases, brief nutri-
tional information [14-17,20].
Interventions lasted between 2 and 12 months. The
mean duration of interventions (excluding the one of
Brown and Smith [26] who did not provide information)
is about 18 weeks. Three studies reported follow-up
Figure 1 Stages of systematic review and meta-analysis.
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ried out in Europe, United States of America (USA),
Asia and Australia.
More detailed information on the characteristics of the
studies is reported in Table 1 and in the paragraph “Het-
erogeneity of studies”.Risk of bias
The assessment of risk of bias is presented in Figure 2
and Additional file 1: Table S1. Only few studies describe
random sequence generation [15,26,31] while none
describes allocation concealment. None of the trials has
a double-blind design. Three of them are single-blind
trials [15,19,26], however in one of the studies it is stated
that blinding of assessors was occasionally difficult to
achieve [15]. Mauri et al. [32] and Khazaal et al. [20]
have an open-label design. The remaining studies do not
report information on blinding. Four studies report only
data for completers [14,17,19,21] and thus do not ad-
dress incomplete data adequately. Seven studies included
all the subjects in the analyses or provided intention-to-
treat analysis [12,13,15,16,26,30,32]. It should be noted
that poor quality randomisation can produce unequal
groups at baseline: Such might be the case of some stud-
ies in this review [20,26]. In Weber & Wyne [19] sub-
jects were given $5 for each complete visit.Results for all interventions
The main analysis (Figure 3) shows an effect toward
the experimental groups, with a reduction in mean
BMI of −0.98 kg/m2, compared to the control groups
(95% CI: -1.31 kg/m2 to −0.65 kg/m2). A statistical
test for heterogeneity failed to suggest substantial
heterogeneity.Drop-outs
There are no significant differences in the number of
drop-outs between experimental and control groups
(OR= 1.08 95% CI 0.67 to 1.73), except for Evans et al.
[14], which has a greater number of drop-outs in the
control group. In that trial, 6 of the 11 drop-outs in the
control group are due to discontinuation or non-
adherence regarding olanzapine treatment (introduced
at the beginning of treatment) and 5 are due to non-
contactable issues.Subgroup analyses
Subgroup analyses (Table 2) demonstrate that studies
about weight gain prevention with individual psychoedu-
cational programmes that include diet and/or physical
activity seem to have the highest impact. However, it is
also true that a greater sample size relates to a greater
heterogeneity and smaller effect size, except for the
comparison between CBT and psychoeducation, where
the contrary is true. Concerning the length of illness,
both studies with chronic patients and first-episode
patients seem to have similar effects. The study with
mixed sample seems to be more successful in the reduc-
tion of weight.Sensitivity analyses
We performed sensitivity analyses to assess the robust-
ness of the findings with respect to: a) the choice of
fixed-effect or random-effects methods, b) the exclusion
of studies that provided only BMI values instead of BMI
changes, c) the exclusion of trials with a duration of less
than 12 weeks or more than 1 year, d) the exclusion of
trials with control groups that are not completely
inactive.
Table 1 Characteristics of randomised controlled trials of lifestyle interventions for weight gain in psychosis
Study
(year)
Sample
size
Participants/
setting
Diagnosis Antipsychotic
medication
Primary
outcomes
Intervention Control Duration* Followup**
Álvarez
Jiménez
et al.
(2006)
[15]
(a) 28 Outpatients Schizophrenia,
schizophreniform
disorder,
schizoaffective
disorder,
delusional
disorder, brief
reactive psychosis,
or psychosis not
otherwise
specified (NOS)
Olanzapine,
risperidone,
haloperidol
- Body weight 10 to 14 individual
sessions (weight
check, agenda
setting, review of
self monitoring
records, homework
assignments)
provided by
clinical psychologists
Usual care +
nonstructured
information about
weight gain and
encouragement to
limit food intake
and/or increase
physical activity
12 0
(b) 33 - BMI change
- Percentage of
patients whose
weight increased
by more than 7 %
of the initial
weight
Brar et al.
(2005)
[13]
(a) 35 Outpatients
or stable
long-term
inpatients
Schizophrenia
(38),
Schizoaffective
disorder (33)
Risperidone Body weight
change
20 group-based
behavioural treatment
sessions
for weight loss
(manual driven
didactic programme)
Usual care 14 0
(b) 37 Concomitant
medications:
sedative-hypnotics,
antidepressants
Brown &
Smith
(2009)
[29]
(a) 15 Outpatients Schizophrenia
(11), bipolar
disorder (5),
depression (9),
borderline
personality
disorder (3)
Weight gain drugs
(not specified)
Body weight
change
5 semistructured
health promotion
sessions using an
operational manual
based on
motivational
interviewing, education,
diary keeping, and
facilitation of access
to mainstream
facilities, facilitated by
mental health key
workers
Usual care N/A 0
(b) 11
Evans
et al.
(2005)
[14]
(a) 29 Outpatients Schizophrenia
(16),
Schizoaffective
disorder (11),
schizophreniform
psychosis (10),
bipolar disorder
(8), depression (5)
Olanzapine - Body weight 6 individual nutritional
education sessions
conducted by an
accredited practicing
dietician
Passive nutritional
education from
the booklet “Food
for the mind”
12 12
(b) 22 - BMI change
- Waist
circumference
change
Forsberg
et al.
(2008)
[27]
(a) 27 Supported
housing
facilities
Schizophrenia
(23), bipolar
disorder (3), other
psychotic
disorders (7), other
psychiatric
diagnoses (8)
Antipsychotic
medication
- Weight Programme for healthy
living: 2 sessions weekly
focusing on the cooking
of good nourishing
food and on physical
activity (indoor and
outdoor activities) lead
by a circle leader (no
training in mental
“aesthetic study
circle” (learn and
practice artistic
techniques)
52 0
(b) 19 - Waist
- BMI
- Physiological
values
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Table 1 Characteristics of randomised controlled trials of lifestyle interventions for weight gain in psychosis (Continued)
health field and no own
experience of working
with person with
psychiatric disabilities
but has a personal
interest in healthy
food and experience
as a fitness instructor)
Khazaal
et al.
(2007)
[20]
(a) 31 Outpatients Schizophrenia and
schizoaffective
disorders (73.8 %),
bipolar disorder
(8.2 %),
schizotypal
disorder (6.6 %),
other (11.5 %)
Olanzapine,
risperidone,
clozapine,
quetiapine,
amisulpride,
classical
antipsychotics
- Body weight 12 2-hour group
sessions weekly
(motivational interview),
tasting sessions,
psychoeducation on
links between weight
gain and antipsychotics,
food intake moderation
prescribed, provided by
two psychologists
Brief Nutritional
Education (one
informative 2
hour group session)
12 3
(b) 30 - BMI
- Eating and
weight-related
cognitions
(MAC-R)
- Binge eating
simptomatology
(SCID-IV)
Kwon
et al.
(2006)
[16]
(a) 33 Outpatients Schizophrenia or
schizoaffective
disorder
Olanzapine - Body weight Diet and exercise
management
programme based
on cognitive and
behavioural therapy,
nutritional education,
diary and exercise
lead respectively by a
dietician and an
exercise coordinator
Usual care +
recommendations
as to physical
activity and eating
12 0
(b) 15 - BMI
Littrell
et al.
(2003)
(a) 35 Outpatients Schizophrenia
(54),
schizoaffective
disorder (16)
Olanzapine - Body weight 16 1-hour
psychoeducation classes
using the "Solutions of
wellness" modules
("Nutrition, wellness and
living a healthy lifestyle",
"Fitness and exercise")
held by a clinician
Usual care +
olanzapine
16 8
(b) 35 Concomitant
medications:
lithium, valproate,
SSRI
- BMI
Mauri
et al.
(2008)
[28]
(a) 21 Outpatients Bipolar I disorder
(41), bipolar II
disorder (2),
depressive
disorder with
psychotic
symptoms (1)
Olanzapine - Body weight dietary group
programme for weight
control: 30-minutes
psychoeducational
meetings + diet
N/A 12 0
(b) 27 - BMI
McKibbin
et al.
(2006)
[17]
(a) 32 Board-and-
care and
community
clubhouse
Schizophrenia
(48),
schizoaffective
disorder (9)
Antipsychotics - Body weight 24 weekly, 90 min
sessions addressing
diabetes education,
nutrition, and lifestyle
exercise conducted by
healthcare providers,
Usual care +
3 brochures
from American
Diabetes
Association
24 0
(b) 32 - BMI
- Waist
circumference
change
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Table 1 Characteristics of randomised controlled trials of lifestyle interventions for weight gain in psychosis (Continued)
dieticians, and diabetes
educators
Milano
et al.
(2007)
[26]
(a) 22 Outpatients Schizophrenia or
manic episodes
in bipolar disease
Olanzapine - Body weight
change
Psychoeducational
programme with
information on correct
alimentary practices and
personal health; diet
(reduction of 500 kcal/
die); programme on
physical exercise (3/wk,
30-60 min)
Regular diet,
no physical
activity
8 0
(b) 14
- BMI
Weber &
Wyne
(2006)
[19]
(a) 8 Outpatients Schizophrenia or
schizoaffective
disorder
One oral atypical
antipsychotic
- Body weight 1-hour group session
based on cognitive-
behavioural strategies to
promote risk reduction
(with food and activity
diary) provided by a
trained psychiatric nurse
practitioner supervised
weekly
Usual care 16 16
(b) 9 - BMI
- Waist-hip ratio
- Blood glucose
level
Wu et al.
(2007)
[21]
(a) 28 Hospitalized
patients
Schizophrenia Clozapine - Body weight Dietary control by a
registered dietician.
1-hour physical activity
sessions 3 times a week
N/A 24 0
(b) 28 - BMI
- Body fat
- Waist-hip ratio
(a) experimental group.
(b) control group.
*number of weeks.
**follow-up assessment, number of weeks after the end of intervention.
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Figure 2 Risk of bias graph.
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Even though our analysis did not detect statistically sig-
nificant heterogeneity, study samples are heterogeneous
according to mean initial weight, length of illness, diag-
nosis, and pharmacological therapy. In 5 of the 13 stud-
ies, both the experimental and the control group at
baseline have a mean BMI in the obesity category (30–
39.9 kg/m2) [17,19,21,26,32]. In 3 studies the mean BMI
of the experimental and control subjects falls into the
overweight category (25–29.9 kg/m2) [12,14,16]. One
study included subjects with a mean BMI in the normal
category [15]. In Milano et al. [30], Forsberg et al. [31]
and Khazaal et al. [20], the control group falls into a
lower category of BMI when compared to the experi-
mental group. In the remaining study mean BMI at
baseline is not known [13], but one of the inclusion cri-
teria is BMI > 26. Such differences in weight at the be-
ginning of intervention may have a role in influencing
the total intervention effect. It is important to note that
most studies on weight gain prevention included normal
weight or overweight subjects whereas studies on weight
loss included obese or overweight subjects. We included
only those studies with at least 50% psychotic patients,
although most authors include other diagnoses in their
studies. However, all patients take antipsychotics. In one
of the studies the sample consisted of drug-naïve first-
episode patients [17]. The length of illness varies (fromFigure 3 Efficacy of lifestyle interventions (Experimental) vs. treatmenfirst-episode patients to chronic patients) with a max-
imum length of about 26 years. The mean age is also
variable. At times in the same study, some patients take
typical antipsychotics while others take atypical antipsy-
chotics that may be for specific study purposes only
[12,14,15,30]. Some authors do not specify the type of
antipsychotic therapy used in their study [17,19,27,29].
Trials are also heterogeneous according to objectives
(weight gain prevention or weight loss), type and dur-
ation of interventions (presence or absence of diet and/
or physical activity, psychoeducation or CBT, duration,
follow-up etc.), background/training of professionals,
control group (treatment as usual, informative booklets
or sessions, treatment not specified), and methodological
sophistication. It must be stated that it is very difficult to
properly perform RCTs in this field due to the amount
of external confounding influences [33]. A number of
studies lack a description of the randomisation proced-
ure. For further information on randomisation and
methodological characteristics of the studies refer to
Additional file 1: Table S1.
Discussion
The results of the meta-analysis show that when com-
pared to treatment as usual, preventive and individual
lifestyle interventions including diet and physical activity
generally reduce weight in psychotic patients by −0.98t as usual (Control) for weight management in psychosis.
Table 2 Subgroup analyses
Subgroups Number of studies Number of subjects MD (CI)* I2
Weight gain prevention 4 (a) 108 (b) 93 - 1.09 (−1.51, -0.68) 0 %
Weight loss 9 (a) 203 (b) 179 −0.86 (−1.38, -0.33) 49 %
Group intervention 9 (a) 203 (b) 189 −0.70 (−1.24, -0.15) 37 %
Individual intervention 4 (a) 108 (b) 83 −1.20 (−1.57, -0.83) 8 %
CBT 5 (a) 124 (b) 114 −0.66 (−1.15, -0.16) 41 %
Psychoeducation 8 (a) 187 (b) 158 −1.28 (−1.64, -0.93) 0 %
First-episode psychosis 1 (a) 28 (b) 33 −0.99 (−1.71, -0.27) N/A
Chronic psychosis 11 (a) 260 (b) 228 −0.92 (−1.34, -0.49) 39 %
Mixed sample 1 (a) 23 (b) 11 −1.30 (−2.02, -0.58) N/A
Physical activity 4 (a) 93 (b) 90 −1.22 (−1.59, -0.85) 2 %
No physical activity 9 (a) 218 (b) 182 −0.75 (−1.22, -0.28) 27 %
Diet 3 (a) 65 (b) 57 −1.31 (−1.78, -0.83) 21 %
No diet 10 (a) 246 (b) 215 −0.80 (−1.19, -0.42) 20 %
* Random-effects method, 95% CI.
(a) experimental group.
(b) control group.
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3.12% of the initial weight (31.36 kg/m2, except [13], for
which we do not have baseline BMI data). However, a
weight loss of 5% to 10% is the criterion for success pro-
posed by the National Institute of Health/National Heart
Lung and Blood Institute, the World Health
Organization, and the Dietary Guidelines for Americans.
Nonetheless, even though a 3.12% loss is below percen-
tages reported as sufficient to improve weight-related
complications including hypertension, type II diabetes,
and dyslipidemia [34-36], Gabriele et al. [37] state that
in individuals taking atypical antipsychotics, outcomes
associated with metabolic risk factors may have greater
health implications than weight changes alone. There-
fore, in addition to weight measurements, the assess-
ment of metabolic parameters should also constitute
integral part of physical health monitoring in people
with mental disorders, because it can provide meaning-
ful information on weight-related health status.
Poor results of weight management interventions can
be due to their short duration or to their lack of follow-
up sessions. The mean duration of interventions in the
trials included is only about 18 weeks with a median of
12 weeks. The lack of follow-up is evidenced by the fact
that out of the 13 trials, only 3 provided follow-up ses-
sions, one after 2 and the other two after 3 months
[12,14,20]. Álvarez Jiménez et al. [15] and McKibbin
et al. [17] did expand their studies with a 2-year and a 6-
month follow-up respectively [38,39]. It is significant
that in the general population, obese patients treated
with behaviour therapy for 20 to 30 weeks typically re-
gain about 30% to 35% of their lost weight in the year
following treatment [40]. Although studies do not yetprovide clear evidence as to the optimum length of en-
gagement in these programmes, experience in the gen-
eral population suggests that lifestyle change needs to be
permanent [41]. Thus, intervention programmes should
last at least 20 weeks and should provide follow-ups
consisting of booster sessions for behavioural control
and for diet and physical activity control. In any case, at-
tention should be brought to the fact that an 18 week
follow-up is a very short period of time compared to the
estimated 25 years of life which are lost in these patients
due to metabolic syndrome [42].
Strengths of the study
Scientific research in this field is relatively new. Differ-
ences between countries regarding resources, physical
and mental health services, and attitudes toward physical
and mental illness can be expected to produce wide var-
iations in physical health care for patients with SMI [43].
This review contributes to the update of available evi-
dence and it highlights the fact that in recent years,
interest of both researchers and clinicians toward the
physical health of mental patients has increased. Thus,
we are witnessing a rise in the number of studies on
physical comorbidity in this population. Most of the
studies are conducted in outpatient settings located in
Europe or USA, except for the one inpatient setting
located in Asia. More and more mental patients are trea-
ted in the community, where they may receive less phys-
ical health attention than hospitalised patients, and
precisely for this reason it is important to focus on the
health status of outpatients. It is also important to point
out that the homogeneity in the setting of the studies is
useful for testing feasibility of interventions in routine
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the current requirements of psychiatric services, which
prove to be the right setting for physical health care in
this particular population. According to Chaudhry and
colleagues [44], the physical health of hospitalised
patients is closely monitored (although some simple and
relevant indexes, e.g., waist circumference, are usually
not recorded routinely). However, in the case of adverse
effects, switching antipsychotic therapy is more likely to
be considered for neurological side effects rather than
for abnormal lab findings such as those of the metabolic
syndrome. Dangers arising from metabolic disturbances
are not yet fully appreciated. Patients in the community
are an urgent priority for improved monitoring and
long-term management [44]. This seems feasible. In fact,
we found a lack of statistically significant differences in
the number of drop-outs between experimental and con-
trol groups, which suggests that dropping-out depends
on factors not related to the feasibility and acceptability
of the interventions per se. Physical screening and moni-
toring programmes may be well accepted by patients
and can be implemented in a variety of settings.Limitations
Limitations at study level
A notable limitation at study level regards heterogeneity,
which has been presented in Results (“Heterogeneity of
studies”).Limitations at review level
We conducted a methodical search of literature to find
every relevant trial for our research question. However,
we do not exclude the possibility of reporting bias.
It must also be taken into account that the following
factors may have influenced the results of the meta-
analysis:
– few studies describe the randomisation method;
– no study describes allocation concealment;
– few studies describe blinding;
– some studies only report data for completers or do
not report the reasons for missing data;
– in one study subjects received money for their
participation (Additional file 1: Table S1).
With respect to informativeness, 4 studies out of 17
did not include data essential to carry out a meta-ana-
lysis, therefore we were forced to exclude them from our
review. Other papers lack information on reasons for
missing data and do not use approaches to deal with
missing outcome data, such as intention-to-treat analysis
or “last observation carried forward”. This may be a
problem because missing outcome data, due to attrition(drop-out) during the study or exclusions from the ana-
lysis, raise the possibility of a bias in the observed effect
estimate [24].
Implications for future research
As to research methodology, more comparable and more
rigorous research methods would be advantageous. This
would facilitate the comparisons and the testing of pos-
sible confounding factors and methodological biases on
the outcome of interventions, and subsequently on the
result of meta-analyses. Greater sample sizes and more
studies would be necessary. More information on the
cost-effectiveness of interventions would also be of use.
Information on missing data in trials would need to be
provided as it is crucial for the understanding of their
influence on outcome, efficacy, and effectiveness of pro-
posed interventions.
As to intervention methodology, it is important for
professionals to have a more homogeneous background
or at least a psychiatric professional background. Besides
weight measurement, the measurement of both obesity-
related physical health parameters (such as waist cir-
cumference) and metabolic parameters, should be con-
sidered mandatory in future protocols. The individual
components of the metabolic syndrome, as well as some
other non-metabolic parameters, should be checked at
baseline and measured regularly thereafter (especially in
drug- naïve first-episode patients, children and adoles-
cents) [45]. In the present review some, but not all trials
included such secondary outcomes.
Conclusions
The studies reviewed are still to be considered prelimin-
ary. Our hope is that this paper will be a small but in-
spiring step toward the development of larger and much
longer studies. Although the findings of this paper are to
be regarded as of a preliminary nature, it is hoped that
they will be instrumental in bringing this problem to the
attention of medical practitioners world-wide. It is clear
that more research is required, especially with an in-
crease in the number of parameters under study. How-
ever, it is also clear that patients with SMI are willing to
participate and remain in health promotion pro-
grammes. Consequently, these programmes may have
positive effects in diminishing risk factors, with relevant
impact on clinical practice.
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